127 related articles for article (PubMed ID: 9154170)
1. Clinical development plan: dehydroepiandrosterone (DHEA).
J Cell Biochem Suppl; 1996; 26():86-99. PubMed ID: 9154170
[No Abstract] [Full Text] [Related]
2. Clinical development plan: genistein.
J Cell Biochem Suppl; 1996; 26():114-26. PubMed ID: 9154172
[No Abstract] [Full Text] [Related]
3. Clinical development plan: 1,4-penylenebis(methylene)selenocyanate.
J Cell Biochem Suppl; 1996; 26():219-26. PubMed ID: 9154179
[No Abstract] [Full Text] [Related]
4. Clinical development plan: sulindac sulfone.
J Cell Biochem Suppl; 1996; 26():227-35. PubMed ID: 9154180
[No Abstract] [Full Text] [Related]
5. Clinical development plan: phenethyl isothiocyanate.
J Cell Biochem Suppl; 1996; 26():149-57. PubMed ID: 9154175
[No Abstract] [Full Text] [Related]
6. Clinical development plan: curcumin.
J Cell Biochem Suppl; 1996; 26():72-85. PubMed ID: 9154169
[No Abstract] [Full Text] [Related]
7. Clinical development plan: 13-cis-retinoic acid.
J Cell Biochem Suppl; 1996; 26():168-201. PubMed ID: 9154177
[No Abstract] [Full Text] [Related]
8. Clinical development plan: vitamin A.
J Cell Biochem Suppl; 1996; 26():269-307. PubMed ID: 9154183
[No Abstract] [Full Text] [Related]
9. Clinical development plan: indole-3-carbinol.
J Cell Biochem Suppl; 1996; 26():127-36. PubMed ID: 9154173
[No Abstract] [Full Text] [Related]
10. Clinical development plan: (+)-vorozole.
J Cell Biochem Suppl; 1996; 26():308-15. PubMed ID: 9154184
[No Abstract] [Full Text] [Related]
11. Clinical development plan: l-Selenomethionine.
J Cell Biochem Suppl; 1996; 26():202-18. PubMed ID: 9154178
[No Abstract] [Full Text] [Related]
12. Clinical development plan: ursodiol.
J Cell Biochem Suppl; 1996; 26():258-68. PubMed ID: 9154182
[No Abstract] [Full Text] [Related]
13. Clinical development plan: tea extracts. Green tea polyphenols. Epigallocatechin gallate.
J Cell Biochem Suppl; 1996; 26():236-57. PubMed ID: 9154181
[No Abstract] [Full Text] [Related]
14. Clinical development plan: folic acid.
J Cell Biochem Suppl; 1996; 26():100-13. PubMed ID: 9154171
[No Abstract] [Full Text] [Related]
15. Clinical development plan: l-perillyl alcohol.
J Cell Biochem Suppl; 1996; 26():137-48. PubMed ID: 9154174
[No Abstract] [Full Text] [Related]
16. Clinical development plan: 9-cis-retinoic acid.
J Cell Biochem Suppl; 1996; 26():158-67. PubMed ID: 9154176
[No Abstract] [Full Text] [Related]
17. [Studies on the anti-tumorpromotion activities of dehydroepiandrosterone and its mechanism of action].
Yang S; Fu ZD; Han R
Yao Xue Xue Bao; 2001 Aug; 36(8):576-80. PubMed ID: 12579932
[TBL] [Abstract][Full Text] [Related]
18. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
19. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice.
Hursting SD; Perkins SN; Haines DC; Ward JM; Phang JM
Cancer Res; 1995 Sep; 55(18):3949-53. PubMed ID: 7664260
[TBL] [Abstract][Full Text] [Related]
20. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
